Annual report pursuant to Section 13 and 15(d)

Note 10 - Income Taxes

Note 10 - Income Taxes

12 Months Ended

Jun. 30, 2016

Note 10. Income Taxes:

The provisions for income taxes consist of the following (in thousands):

	Year Ended June 30,
	201 6			201 5			201 4
Earnings before income taxes consist of:
Domestic	$	120,154		$	121,765		$	127,681
Foreign		27,327			32,397			33,711
	$	147,481		$	154,162		$	161,392
Taxes on income consist of:
Currently payable:
Federal	$	34,805		$	28,220		$	40,967
State		2,958			6,165			1,709
Foreign		7,579			10,704			10,668
Net deferred:
Federal		1,906			4,401			(1,137	)
State		(428	)		292			(41	)
Foreign		(3,815	)		(3,355	)		(1,722	)
	$	43,005		$	46,427		$	50,444

The following is a reconciliation of the federal tax calculated at the statutory rate of 35% to the actual income taxes provided (in thousands):

	Year Ended June 30,
	201 6			201 5			201 4

Computed expected federal income tax expense	$	51,618		$	53,957		$	56,487
State income taxes, net of federal benefit		1,852			4,762			1,048
Qualified production activity deduction		(3,932	)		(3,140	)		(3,823	)
Non-taxable gain on investment		0			(2,905	)		0
Research and development tax credit		(1,550	)		(912	)		(476	)
Tax-exempt interest		0			0			(654	)
Foreign tax rate differences		(4,639	)		(4,059	)		(2,857	)
Other		(344	)		(1,276	)		719
	$	43,005		$	46,427		$	50,444

The effective rate for June 30, 2016 decreased by 0.9% compared to the prior year. The rate decrease was primarily driven by additional R&D credit benefit due to the retroactive reinstatement of the credit under the Protecting Americans from Tax Hikes Act of 2015, an increase in the foreign rate benefit due to the reduction in the UK income tax rate and a reduction in state tax related to the prior year. These decreases were partially offset by less of a foreign tax credit benefit than in the prior year and the non recurrence of a non-taxable gain.

In the year ended June 30, 2015, as a result of the recent acquisitions, the rate reflects an increase for state tax expense as well as a resulting provision to return true up from fiscal 2014. This increase is offset by the non-taxable gain which was a result of purchasing the remaining interest in CyVek. In addition the Company‘s R&D Europe subsidiary declared and paid a dividend of £46.6 million which resulted in a tax benefit of approximately $1.7 million.

Temporary differences comprising deferred taxes on the Consolidated Balance Sheets are as follows (in thousands):

	June 30
	201 6			201 5

Inventory	$	9,768		$	8,753
Net operating loss carryovers		26,556			34,767
Tax credit carryovers		3,197			3,872
Excess tax basis in equity investments		4,544			4,496
Deferred compensation		5,912			3,747
Net unrealized loss on available for sale investment		329			0
Other		7,421			4,712
Valuation allowance		(7,201	)		(2,558	)
Net deferred tax assets		50,526			57,789

Net unrealized gain on available-for-sale investments		0			(8,446	)
Intangible asset amortization		(107,200	)		(96,401	)
Depreciation		(5,132	)		(2,394	)
Other		(1,031	)		(466	)
Deferred tax liabilities		(113,363	)		(107,707	)
Net deferred tax liabilities	$	(62,837	)	$	(49,918	)

A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. At June 30, 2016, a valuation allowance for potential capital loss carryovers on equity investments was $5.0 million. Approximately $2.0 million of the valuation allowance at June 30, 2016 is for certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired Novus, ProteinSimple, and CyVek. The remainder of the valuation allowance is for certain state tax credit carryovers generated in fiscal 2016 and 2015. The Company believes it is more likely than not that these tax carryovers will not be realized. At June 30, 2015, a valuation allowance for potential capital loss carryovers on equity investments was zero. Approximately $2.4 million of the valuation allowance at June 30, 2015 was for acquisition related foreign and state tax net operating loss and state credit carryforwards. The remainder of the valuation allowance was for certain state tax credit carryovers generated in fiscal 2015.

The valuation allowance as of June 30, 2016 was $7.2 million which is an increase of $4.7 million over prior year. This increase included a $5.0 million change related to an investment and was recorded through other comprehensive income and was partially offset by a decrease of $0.3 million primarily related to the utilization of expiation of state net operating loss carry forwards and research and development credits.

At June 30, 2016, the Company has federal and state net operating loss carryforwards of approximately $63.9 million and $71.6 million, respectively, from its fiscal 2015 acquisitions of ProteinSimple and CyVek, which are not limited under IRC Section 382. At June 30, 2016, the Company has foreign net operating loss carryforwards of $2.1 million from its fiscal 2015 acquisition of Novus. The net operating loss carryforwards expire between fiscal 2017 and 2034. The Company has a deferred tax asset of $24.9 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. At June 30, 2016, the Company has federal and state tax credit carryforwards of $1.7 million and $1.3 million, respectively. The federal tax credit carryforwards expire between 2018 and 2035. The state credit carryforwards have no expiry date. The Company has a deferred tax asset of $3.6 million, net of the valuation allowance discussed above, related to the tax credit carryovers.

The Company has not recognized a deferred tax liability for unremitted earnings of approximately $57.6 million from its foreign operations because its subsidiaries have invested or will invest the undistributed earnings indefinitely, or the earnings will be remitted in a tax-neutral transaction. Generally, such amounts become subject to United States taxation upon the remittance of dividends and under other circumstances. It is not practical to estimate the amount of the deferred income tax liabilities related to investments in these foreign subsidiaries.

The Company’s unrecognized tax benefits at June 30, 2016, 2015 and 2014, including accrued interest and penalties, were not material. The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelve months. The Company files income tax returns in the U.S federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company’s federal returns are subject to tax assessment for 2013 and subsequent years. State and foreign income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.